Cargando…

Comparative Therapeutic Efficacy of (153)Sm-EDTMP and (177)Lu-EDTMP for Bone Pain Palliation in Patients with Skeletal Metastases: Patients’ Pain Score Analysis and Personalized Dosimetry

INTRODUCTION: The aim of the present study was to compare the therapeutic efficacy of (153)Sm-EDTMP and (177)Lu-EDTMP in pain palliation in cancer patients with skeletal metastases. MATERIALS AND METHODS: Thirty patients (25 M:5 F, mean age: 66.0 ± 14.7 years) of breast/prostate cancer with document...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Sarika, Singh, Baljinder, Koul, Ashwani, Mittal, Bhagwant Rai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410571/ https://www.ncbi.nlm.nih.gov/pubmed/28507988 http://dx.doi.org/10.3389/fmed.2017.00046

Ejemplares similares

Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis
por: Ayati, Narjess, et al.
Publicado: (2013)

Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical
por: Mercanoglu, Guldem, et al.
Publicado: (2023)

Beyond Palliation: Therapeutic Applications of (153)Samarium-EDTMP
por: Wilky, Breelyn A., et al.
Publicado: (2013)

Production, Quality Control and Pharmacokinetic Studies of (177)Lu-EDTMP for Human Bone Pain Palliation Therapy Trials
por: Bahrami-Samani, Ali, et al.
Publicado: (2012)

Radionuclide Treatment with 153Sm-EDTMP is Effective for the Palliation of Bone Pain in the Context of Extensive Bone Marrow Metastases: A Case Report
por: Kairemo, Kalevi, et al.
Publicado: (2014)

Effects of low-dose capecitabine on Samarium-153-EDTMP therapy for painful bone metastases
por: Barai, Sukanta, et al.
Publicado: (2015)

Comparison of Tc-99m MDP and Sm-153 EDTMP bone scan
por: Ramachandran, Krishnakumar, et al.
Publicado: (2011)

Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats
por: Yousefnia, Hassan, et al.
Publicado: (2015)

Toxicity of Therapy with Sm-153-EDTMP: To What Extend can it be Related to the Tumor Type?
por: Świętaszczyk, Cyprian, et al.
Publicado: (2016)

Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases
por: Lam, Marnix G. E. H., et al.
Publicado: (2007)

Treatment of severe hypocalcaemia due to osteoblastic metastases in a patient with post-thyroidectomy hypoparathyroidism with (153)Sm-EDTMP
por: Kassi, Eva, et al.
Publicado: (2017)

Production, quality control, and bio-distribution studies of (159)Gd-EDTMP as a palliative agent for bone pain
por: Arani*, Simindokht Shirvani, et al.
Publicado: (2015)

The Level of Europium-154 Contaminating Samarium-153-EDTMP Activates the Radiation Alarm System at the US Homeland Security Checkpoints
por: Najeeb Al Hallak, Mohammed, et al.
Publicado: (2009)

Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
por: Keeling, A. A., et al.
Publicado: (1989)

Samarium-153-EDTMP (Quadramet(®)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial
por: Heery, Christopher R., et al.
Publicado: (2016)

Production, Quality Control and Pharmacokinetic Studies of (166)Ho-EDTMP for Therapeutic Applications
por: Bahrami-Samani, Ali, et al.
Publicado: (2010)

Deviation in the predefined calibration factors of the dose calibrators and the associated inaccuracy in the radioactivity measurements of beta-gamma emitters
por: Sharma, Sarika, et al.
Publicado: (2015)

sup 8 sup 9 Sr and sup 1 sup 5 sup 3 Sm-EDTMP therapy of disseminated skeletal metastasis
por: Zhang Jun Ning, et al.
Publicado: (2001)

The influence of EDTMP-concentration on the biodistribution of radio-lanthanides and $^{225}$Ac in tumor bearing mice
por: Beyer, Gerd-Jürgen, et al.
Publicado: (1996)

Scutellarin Loaded on Ultradeformable Nanoliposome Scutellarin EDTMP (S-UNL-E) Promotes Osteogenesis in Osteoporotic Rats
por: Teng, Minhua, et al.
Publicado: (2022)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Simultaner Vergleich der Bioverteilung von $^{87}$Y-Citrat and $^{88}$Y-EDTMP tumortragenden Ratten
por: Beyer, Gerd-Jürgen, et al.
Publicado: (1991)

Improved Formulation of (224)Ra-Labeled Calcium Carbonate Microparticles by Surface Layer Encapsulation and Addition of EDTMP
por: Li, Ruth Gong, et al.
Publicado: (2021)

Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases
por: Fernández, René, et al.
Publicado: (2021)

[(177)Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results
por: Yadav, Madhav Prasad, et al.
Publicado: (2020)

Metastatic Bone Pain Palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic Acid
por: Alavi, Mehrosadat, et al.
Publicado: (2015)

Developments in (177)Lu-based radiopharmaceutical therapy and dosimetry
por: George, Siju C., et al.
Publicado: (2023)

Preparation and characterization of scutellarin loaded on ultradeformable nano-liposomes scutellarin EDTMP (S-UNL-E) and in vitro study of its osteogenesis
por: Minhua, Teng, et al.
Publicado: (2022)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Production, biodistribution assessment and dosimetric evaluation of (177)Lu-TTHMP as an agent for bone pain palliation
por: Zolghadri, Samaneh, et al.
Publicado: (2015)

Production and quality control (177)Lu (NCA)—DOTMP as a potential agent for bone pain palliation
por: Salek, Nafise, et al.
Publicado: (2016)

Comparison of different methods for post-therapeutic dosimetry in [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Rosar, Florian, et al.
Publicado: (2021)

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
por: Sjögreen Gleisner, Katarina, et al.
Publicado: (2022)

Feasibility of simplifying renal dosimetry in (177)Lu peptide receptor radionuclide therapy
por: Sundlöv, Anna, et al.
Publicado: (2018)

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized (177)Lu-octreotate PRRT
por: Del Prete, Michela, et al.
Publicado: (2018)

Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
por: Sundlöv, Anna, et al.
Publicado: (2017)

(177)Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial
por: Satapathy, Swayamjeet, et al.
Publicado: (2021)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2kkrevimgpnm50bvm7carbvo5u